Gemphire Therapeutics Inc (NASDAQ:GEMP) shares traded up 8.8% during trading on Thursday . The company traded as high as $1.57 and last traded at $1.46. 5,610 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 1,501,601 shares. The stock had previously closed at $1.60.
A number of research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. Canaccord Genuity reissued a “buy” rating and issued a $6.00 price objective on shares of Gemphire Therapeutics in a research report on Monday, August 13th. Jefferies Financial Group downgraded shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating and set a $15.00 price objective for the company. in a research report on Monday, August 13th. Roth Capital reissued a “neutral” rating and issued a $30.00 price objective on shares of Gemphire Therapeutics in a research report on Friday, August 10th. Finally, Raymond James downgraded shares of Gemphire Therapeutics from an “outperform” rating to a “market perform” rating and set a $22.00 price objective for the company. in a research report on Tuesday, August 7th. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $17.82.
The firm has a market capitalization of $19.97 million, a P/E ratio of -0.50 and a beta of 1.35. The company has a current ratio of 4.64, a quick ratio of 4.64 and a debt-to-equity ratio of 0.50.
Gemphire Therapeutics (NASDAQ:GEMP) last announced its earnings results on Monday, August 13th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.05. equities analysts predict that Gemphire Therapeutics Inc will post -1.99 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in the stock. Bamco Inc. NY boosted its holdings in shares of Gemphire Therapeutics by 33.0% during the 1st quarter. Bamco Inc. NY now owns 510,649 shares of the company’s stock worth $3,324,000 after buying an additional 126,679 shares during the period. Sphera Funds Management LTD. bought a new stake in shares of Gemphire Therapeutics during the 1st quarter worth about $3,132,000. Millennium Management LLC bought a new stake in shares of Gemphire Therapeutics during the 2nd quarter worth about $1,981,000. Highland Capital Management LP bought a new stake in shares of Gemphire Therapeutics during the 1st quarter worth about $700,000. Finally, DAFNA Capital Management LLC bought a new stake in shares of Gemphire Therapeutics during the 1st quarter worth about $651,000. 32.60% of the stock is owned by institutional investors and hedge funds.
Gemphire Therapeutics Company Profile (NASDAQ:GEMP)
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.
Featured Article: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.